KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Basic) (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EPS (Basic) data on record, last reported at $3.3 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 5.43% year-over-year to $3.3; the TTM value through Dec 2025 reached $14.05, up 55.08%, while the annual FY2025 figure was -$5.84, 164.46% down from the prior year.
  • EPS (Basic) reached $3.3 in Q4 2025 per JAZZ's latest filing, down from $4.14 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $4.14 in Q3 2025 and bottomed at -$11.74 in Q2 2025.
  • Average EPS (Basic) over 5 years is $0.13, with a median of $1.09 recorded in 2023.
  • Peak YoY movement for EPS (Basic): plummeted 612.96% in 2022, then skyrocketed 3533.33% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.54 in 2021, then tumbled by 612.96% to -$3.85 in 2022, then soared by 138.96% to $1.5 in 2023, then surged by 108.67% to $3.13 in 2024, then rose by 5.43% to $3.3 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $3.3 in Q4 2025, $4.14 in Q3 2025, and -$11.74 in Q2 2025.